gene therapy

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

Clinical-stage biotech Opus Genetics named to Fast Company's 2026 most innovative companies list for gene therapy work in inherited retinal diseases.

Rosen Law Firm recruits investors for securities class action against REGENXBIO over alleged RGX-111 gene therapy misstatements. Lead plaintiff deadline: April 14, 2026.

Securities lawsuit filed against $RGNX alleging misleading statements about RGX-111 gene therapy. Eligible investors must act before April 14, 2026 deadline.

Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.

Hagens Berman investigates $QURE for misrepresenting FDA interactions on gene therapy AMT-130. Stock crashed 49% after FDA publicly rebuked company's data claims.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.

Taysha Gene Therapies reported $109M 2025 loss while advancing TSHA-102 gene therapy for Rett syndrome with positive safety data and FDA regulatory alignment through 2028.

Rosen Law Firm files securities class action against REGENXBIO for alleged false statements on product safety and efficacy, with April 14, 2026 lead plaintiff deadline.

Class action lawsuit filed against $REGENXBIO alleging false statements on RGX-111 gene therapy. Covers investors from February 2022 to January 2026.

Class action lawsuit filed against $QURE over alleged misstatements about Huntington's disease therapy approval timeline. Stock crashed 49% after FDA stance shift.

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.

CRISPR Therapeutics stock fell 12% after announcing a $350M convertible debt offering. Analysts remain bullish, suggesting the decline may present a buying opportunity.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy. Covers investors from Feb 2022 to Jan 2026; lead plaintiff deadline April 14.

RegenxBio faces securities class action alleging misleading RGX-111 gene therapy claims; investors have until April 14, 2026 to file.

Class action lawsuit filed against $QURE over alleged misstatements about AMT-130 gene therapy FDA approval status. Stock plunged 49% after FDA reversed position on Phase I/II data adequacy.

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

Tenaya Therapeutics surges 31% after partnering with Alnylam on cardiovascular genetic targets, securing $10M upfront and $1.13B in potential milestone payments.

REGENXBIO faces class action lawsuit over RGX-111 gene therapy trial disclosures. Lead plaintiff deadline is April 14, 2026.